Ovation.io snares $5M in series A funding to support growth

money
The company’s flagship product, Ovation Diagnostic, is at the core of what it touts as a rapidly expanding laboratory commercialization platform. (Pixabay)

Ovation.io, a provider of cloud-based lab information systems, reeled in $5 million in series A funding that it plans to use to accelerate lab deployment and expand other features.

The round was led by Madrona Venture Group. Other participants included Borealis Ventures, Nat Turner and Zac Weinberg, as well as existing investors StagedotO and David Shaw.

Ovation.io provides operations and intelligence software for next-generation precision diagnostic labs and focuses on the challenges of critical functional areas of laboratory operations, business analytics and relationship support.

Webinar

How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

“We are excited to be partnering with our new and existing investors to continue supporting diagnostic labs as they play a crucially important role in patient diagnosis and treatment, and in accelerating development of new therapies” Barry Wark, Ovation.io co-founder and chief executive, said in a statement.

The company’s flagship product, Ovation Diagnostic, is at the core of what it touts as a rapidly expanding laboratory commercialization platform.

“Genomics and molecular testing labs have complex workflows that require new functionality that can only come from a modern SaaS and cloud-based solution,” S. Somasegar, Madrona’s managing director, said in a statement. “At the same time, these labs have clinical and genomic data that is being under-utilized to provide improved patient outcomes.”

Read more on

Suggested Articles

U.S.-China biotech Brii Biosciences is pushing out into new territory with a new hire alongside a focus on a new R&D area.

John Ratliff’s position has changed three times this fall, but now, much like the falling leaves, he looks to have settled.

Genesis Drug Discovery & Development has bought up New England Discovery Partners as it looks to boost its synthetic and medicinal chemistry.